【摘要】：目的系統評價英夫利昔單抗治療強直性脊柱炎的療效與安全性。方法在Pub Med、循證醫(yī)學數據庫、Elsevier、Springer、中國知網、維普、萬方等數據庫,檢索1999年11月至2016年6月發(fā)表的英夫利昔單抗聯合甲氨蝶呤對比柳氮磺胺吡啶聯合甲氨蝶呤或英夫利昔單抗對比安慰劑治療強直性脊柱炎的隨機對照臨床試驗,以有效率和不良反應發(fā)生率為結局指標。提取資料后,對符合納入標準的文獻利用Cochrane系統評價手冊5.2和Rev Man5.2軟件進行質量分析和Meta分析。結果共納入10篇文獻,996例研究對象。聯合用藥和單獨用藥試驗組的有效率均顯著高于對照組(分別為RR=1.77,95%CI:1.44~2.17,P0.000 01和RR=2.84,95%CI:2.21~3.65,P0.000 01)。不良反應方面,聯合用藥的兩組無顯著差異(P0.05),而單獨用藥中試驗組的炎性指標異常發(fā)生率高于對照組(P≤0.05)。結論英夫利昔單抗單獨用藥或聯合甲氨蝶呤治療強直性脊柱炎,相比傳統藥物的療效更明確,安全性較好。
[Abstract]:Objective to evaluate the efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Methods Elsevier Springer, China knowledge Network, Weip, Wanfang and other databases were used in Pub Med, Evidence-based Medicine Database. To retrieve the randomized controlled clinical trial of infliximab combined with methotrexate versus sulfamyridine combined with methotrexate or infliximab in the treatment of ankylosing spondylitis published from November 1999 to June 2016. Efficacy and incidence of adverse reactions were taken as outcome indicators. After extracting the data, the quality analysis and Meta analysis were carried out by using Cochrane system evaluation manual 5.2 and Rev Man5.2 software. Results A total of 996 subjects were included in 10 articles. The effective rate of the combined drug group and the single drug group were significantly higher than that of the control group (RR=1.77,95%CI:1.44~2.17,P0.000 01 and RR=2.84,95%CI:2.21~3.65,P0.000 01, respectively). There was no significant difference in adverse reactions between the two groups (P0.05), but the incidence of abnormal inflammatory indexes in the test group was higher than that in the control group (P 鈮，

本文編號：2220689